41 results on '"Santoro, Rosanna"'
Search Results
2. A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms
3. An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response
4. Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study
5. A P70S Variant of the IFNλ4 Protein Displaying Decreased Activity is Associated with Improved Hepatitis C Virus Clearance and Reduced Hepatic Expression of Interferon-Stimulated Genes: 226
6. Peginterferon alfa-2b and ribaviran for 12 vs. 24 weeks in HCV genotype 2 or 3
7. Benefit of weight based dosages of Ribavirin (RBV) in combination with PegInterferon (PegIFN) α2a in naïve patients with HCV2 and HCV3: results of an Italian Randomized Controlled Trial, the WRITE study: 1737
8. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring
9. Inosine Triphosphatase Genetic Variants Are Protective Against Anemia During Antiviral Therapy for Hcv2/3 But Do Not Decrease Dose Reductions of Rbv Or Increase Svr
10. Improvement of all HCV care cascade steps in IVDU treated with DAAs within a dedicated program
11. IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis
12. Progress in promising anti-fibrotic therapies
13. Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
14. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis
15. SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
16. SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study
17. Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis
18. Genome Wide Association Study Identifies Genetic Variants Associated with Early and Sustained Response to (Peg)Interferon in Chronic Hepatitis B Patients: The GIANT-B Study
19. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience
20. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin
21. Erratum: Reduced IFNI 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes(Nature Communications (2014) 5 (5699) 10.1038/ncomms6699)
22. 75
23. Interleukin‐28B genetic variants in untreated Italian HCV‐infected patients: a multicentre study
24. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection
25. Sa1026 Liposome-Encapsulated Silybin and Hepatitis C Virus Infection
26. Il28B Cc-Genotype Association with Hla-Dqb1*0301 Allele Increases the Prediction of Spontaneous HCV RNA Clearance in Thalassaemic HCV-Infected Patients
27. 75: A variant of IFNλ4 displaying decreased activity is associated with better hepatitis C virus clearance and reduced ISG expression
28. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis
29. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.
30. TREATMENT OF PATIENTS WITH ACUTE HCV MONO-INFECTION MAY BE DELAYED AFTER WEEK 24 ACCORDING WITH IL28B SINGLE NUCLEOTIDE POLYMORPHISMS (SNP) RESULTS AND INDEPENDENTLY OF HEPATITIS C VIRUS (HCV) GENOTYPE
31. Benefit of weight based dosages of Ribavirin (RBV) in combination with PegInterferon (PegIFN) alpha 2a in naive patients with HCV2 and HCV3: results of an Italian Randomized Controlled Trial, the WRITE study
32. Liposome-Encapsulated Silybin and Hepatitis C Virus Infection
33. Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C
34. ITPA GENETIC VARIANTS ARE PROTECTIVE AGAINST ANEMIA DURING ANTIVIRAL THERAPY FOR G2/3 HCV, BUT DO NOT DECREASE THE NEED FOR RBV DOSE REDUCTION OR INCREASE SVR
35. Corrigendum: Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.
36. Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.
37. THU393 - Improvement of all HCV care cascade steps in IVDU treated with DAAs within a dedicated program.
38. Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study
39. Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study.
40. Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients.
41. HCV chronic infection and CCR5-delta32/delta32.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.